Home | Life Sciences Intellectual Property Review
WEB5 days ago · The court rejected the medical device company’s auxiliary requests and nixed patent in 17 territories although it seems receptive to these amendments in general, say Laura Orlando and Rachel Montagnon of Herbert Smith Freehills.
Latest News & Features | Life Sciences Intellectual Property Review
WEBSep 3, 2024 · UPC clarifies that evidence must show that pre-launch preparations are complete for threat of imminent infringement to occur | Question remains over how the UPC will deal with the cumulative activities of several companies in a group | Court also broaches key cross-border question.
Americas | Life Sciences Intellectual Property Review
WEB13 February 2024 US Patent and Trademark Office publishes ‘clear’ guidance mandating AI-related patents to have ‘significant’ human involvement | Cites one hypothetical example relating to the development of a compound for treating cancer | Kathi Vidal: ‘patent system was developed to incentivise and protect human ingenuity’.
Unified Patent Court | Life Sciences Intellectual Property Review
WEBA distinctive UPC approach to patent validity and revocations is emerging as the court shows its willingness to break new ground, say Emily Bottle and Sebastian Moore of HSF. Signs show that an uptick of life sciences cases at the Unified Patent Court is likely, but does the court have capacity ...
Preventative IP for preventative pharma healthcare
WEB4 hours ago · The shift towards preventative pharmaceuticals could open new, and highly valuable, markets but it must be strengthened by patent rights, says Sam Andrews, senior paralegal at Powell Gilbert.
Biotechnology | Life Sciences Intellectual Property Review
WEB17 September 2024 Court finds United Therapeutics breached settlement agreement by restricting distribution of cartridges | Sandoz alleged rival hampered launch of generic medication for pulmonary arterial hypertension
Medtech | Life Sciences Intellectual Property Review
WEB26 March 2024 Judge’s dissenting opinion challenges the interpretation of the safe harbour provision by the US Court of Appeals for the Federal Circuit | Decision concerns Meril's importation of transcatheter heart valve systems in a dispute with Edwards Lifesciences | Court majority upheld the district court's ruling favouring Meril.
CRISPR | Life Sciences Intellectual Property Review
WEB9 November 2020 The European Patent Office has released the long-awaited reasoning for its decision to uphold the revocation of a Broad Institute CRISPR/Cas9 patent. In January this year, the EPO’s Board of Appeal concluded that the Broad’s patent, EP2,771,468, lacked novelty due to an invalid claim to priority.
Case review: Biogen v Medeva, 20 years on
WEBMar 25, 2015 · Case review: Biogen v Medeva, 20 years on. It may be hard to imagine Napoleon and the Duke of Wellington sitting down to reminisce after the Battle of Waterloo, and it’s perhaps just as hard to imagine warring legal parties doing so …
EPO’s new examination guidelines: what you need to know
WEBApr 6, 2021 · A new edition of the European Patent Office (EPO) Guidelines for Examination came into force on March 1, 2021. Relevant to life sciences, this edition includes a new subsection detailing EPO practice with respect to the interpretation of terms relating to amino or nucleic acid sequences, as well as a new section on the examination of claims to antibodies.